Pipeline and BC 007 Mode of Action
Our candidate BC 007 is a non-modified DNA aptamer that binds to and leads to the neutralization of autoantibodies that are directed against G-protein-coupled receptors (GPCR-AABs). E.g., BC 007 binds to ß1-adrenergic-receptor-autoantibodies as found in patients with Cardiomyopathy. BC 007 also binds to antibodies to other G-protein-coupled receptors which are found in in different autoimmune diseases as well as in Long-Covid patients.
BC 007 was successfully tested in a Phase-1 clinical trial. This study included a sub-group of subjects that are tested positive for GPCR-autoantibodies and which are otherwise healthy. The study design allowed for the proof that BC007 can neutralize GPCR-autoantibodies in humans. The full study design is published on clinicaltrials.gov
After successful completion of Phase 1/1b, we initiated a multi-center, randomised, controlled Phase 2 study in heart failure patients.
Mode of Action
This video sequence demonstrates the mechanism of action of BC 007